Arm 3

Phase 2

SSun Yat-sen University

Arm 3 is one of 5 therapeutic programs targeting CRC (Colorectal Cancer). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

CRC (colorectal Cancer)Not yet recruiting

CRC (colorectal Cancer)Phase 2

Not yet recruiting

Competition

Competitive Landscape

5 competitors in CRC (colorectal Cancer)

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

2 2

INCA33890

Incyte

Phase 3

2 3

PM8002

BBiotheus Inc.

Phase 2

1 4

Arm 3

SSun Yat-sen University

Phase 2

1 5

Arm1

TTata Memorial Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Not yet recruiting

CRC (colorectal Cancer)

NCT07714447

Clinical

Trials by Indication[1]

CRC (Colorectal Cancer)1 trial

Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer: a Multicentre, Multicohort, Phase 2 Trial.

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07714447·91 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Arm 3. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Arm 3. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: SSun Yat-sen University

Arm 3

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

CRC (Colorectal Cancer)1 trial

References

Drug Info

Quick Facts

Related News